Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide-R-CHOP for high CNS relapse risk DLBCL
KCT0005165Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Samyang Biopharmaceuticals Corporation. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0005165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005165.